STROKE MANAGEMENT MARKET ANALYSIS

Market News

Key Developments

The narrow range of drugs available for the treatment of stroke offers wide options for research organizations and key players to excel the stroke management market by discovering novel drugs with fewer side-effects. Merger and acquisition is the key strategy to expand the stroke management market. In May 2017, Codman Neuro, a part of Johnson & Johnson, acquired Neuravi Ltd., an Irish medical device company that manufactures advanced revascularization devices and EmboTrap is a device manufactured by this company. The EmboTrap platform was intended to address the critical need for rapid restoration of blood flow in stroke patients and the combination of Neuravi’s expertise in clot research with Codman Neuro’s global resources aims to accelerate development in the field of acute ischemic stroke treatment. Furthermore, a strong therapeutic pipeline of players will enhance the growth of stroke management market. In 2018, NuvOx Pharma’s dodecafluoropentane emulsion (DDFPe) IV entered phase II clinical trials and DDFPe aims to deliver oxygen to the hypoxic tissue of the brain. Also, in 2018, DiaMedica Therapeutics Inc. announced DM199, a recombinant human tissue kallikrein, to enter phase II clinical trial and it is expected to be a breakthrough in stroke treatment.